Teva Pharmaceutical Industries Limited Receives Favorable Court Ruling On Generic Pravachol(R) Exclusivity

JERUSALEM--(BUSINESS WIRE)--Oct. 21, 2005--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. District Court for the District of Columbia has granted the Company's request to enjoin the U.S. Food and Drug Administration from approving subsequent ANDAs for generic Pravastatin Sodium Tablets 10 mg., 20 mg., and 40 mg., until the expiration of Teva's 180-day exclusivity.

Back to news